The discovery that changed everything
In 1992, a scientist named Dr. Raphael Mechoulam made a discovery that should have rewritten medical textbooks around the world. Working at the Hebrew University of Jerusalem, he and his team identified a complex biological system woven into virtually every tissue and organ in the human body, a system so far-reaching in its influence that it touched pain, mood, immune function, memory, metabolism, sleep, fertility, and more, all at once.
They called it the Endocannabinoid System, or ECS.
It was named after the cannabis plant, because it was research into how cannabis compounds interact with the body that led to its discovery. And that single association, with one of the most politically controversial plants on earth, would go on to shape how this system was treated by governments, medical schools, and pharmaceutical companies for the next three decades.
Today, most doctors practising medicine received no meaningful training in the endocannabinoid system during their medical education. It is not a standard feature of medical school curricula. Most patients have never heard of it. And yet it is, by any reasonable measure, one of the most important regulatory systems in the human body.
This document exists to change that, for you.
Your body was built with this system already inside it
Before we discuss what phytocannabinoids are or what our formulations do, there is something fundamental to understand: your body already makes its own cannabinoids.
They are called endocannabinoids, and endogenous simply means produced from within. Your body manufactures these compounds naturally and uses them to send signals throughout your nervous system, immune system, and organs. The cannabis plant produces compounds that closely mimic this internal signalling. That is not a coincidence engineered by science. It is a convergence that exists in nature.
The ECS has three main components.
Endocannabinoids
The messenger molecules your body produces, including anandamide and 2-AG.
Receptors
CB1 and CB2, the docking sites found on cells throughout the body that receive these messages.
Enzymes
A set of enzymes that break down endocannabinoids once they have delivered their signal, keeping the system in balance.
The Result
Working together, these three components keep the body in homeostasis, regulating pain, inflammation, mood, sleep, immune response, appetite, and memory, a continuous adjustment that keeps you well.
When this system is functioning well, it acts as a continuous conversation between your brain and your body, constantly monitoring and adjusting, turning inflammation up when you need it to fight infection and down when the threat has passed, modulating pain signals, stabilising mood, regulating sleep cycles, supporting immune responses, and maintaining what scientists call homeostasis, the biological state of balance in which the body functions at its best.
When this system is depleted or dysfunctional, the consequences show up across nearly every system in the body simultaneously. This is not a coincidence. It is a pattern that researchers have begun to call Clinical Endocannabinoid Deficiency.
The system that does everything
To understand why the ECS matters so much, it helps to understand what it actually governs. Not as a list of functions, but as a picture of what your body is doing every second of every day, beneath your awareness, trying to keep you well.
Your pain response, right now
Through CB1 receptors in your central nervous system and CB2 receptors in peripheral tissues, the ECS modulates how pain signals travel and how intensely they are experienced. It is one of the reasons that two people with the same injury can have entirely different pain experiences. The ECS is the variable.
Your inflammation
It exerts what scientists describe as tonic anti-inflammatory effects, continuously suppressing the production of inflammatory molecules like TNF-alpha and IL-1beta, while simultaneously promoting resolution, the process by which inflammation switches off once its job is done. Chronic inflammation, the kind associated with autoimmune conditions, metabolic disease, and neurological disorders, is increasingly understood as a failure of this resolution process. The ECS is the system responsible for resolution.
Your emotional state
Through its influence on the hypothalamic-pituitary-adrenal axis, the body's stress response system, and its interactions with serotonin and dopamine signalling in the brain, the ECS acts as a buffer against chronic stress and anxiety. It helps encode and extinguish fear memories, which is why researchers studying post-traumatic stress have become increasingly interested in cannabinoid signalling.
Your brain
It promotes neuronal survival, reduces excitotoxicity, the kind of neurological damage that occurs when nerve cells are overactivated, and stimulates the growth of new neurons in regions of the brain involved in learning and memory. This process, called neurogenesis, continues throughout adulthood, and the ECS is one of its primary regulators.
Your gut
Through receptors in the enteric nervous system, often called the gut's own brain, the ECS controls motility, secretion, and barrier integrity. Conditions like irritable bowel syndrome, Crohn's disease, and gut-related immune disorders all involve disruption in pathways where ECS signalling plays a critical role.
Your ECS also influences your cardiovascular system, your bone remodelling, your reproductive function, your metabolic balance, and your body's response to pathogens. It is not an exaggeration to say that the ECS touches almost every physiological process that determines whether you feel well or unwell.
Why your doctor never told you
This question deserves an honest answer, because the answer matters.
The endocannabinoid system was discovered in 1992. The nervous system has been studied for centuries. The cardiovascular system has been studied for centuries. The ECS, by comparison, is a new arrival in the scientific literature, and medicine moves slowly, particularly when political forces are working against it.
For most of the 20th century, cannabis was a Schedule I substance in the United States, meaning it was classified alongside heroin as having no accepted medical use and high abuse potential. Research into cannabinoids required federal approval that was rarely granted. Scientists who wanted to study the plant, and by extension the system it had helped reveal, faced regulatory barriers that effectively shut down entire lines of inquiry for decades.
By the time those barriers began to ease, a generation of medical professionals had already graduated without any meaningful training in endocannabinoid physiology. The curricula were not updated. The textbooks were not revised. The guidelines were not changed. The system remained in a kind of institutional blind spot, known to researchers and almost invisible to the clinicians treating patients every day.
There is also a more uncomfortable truth. You cannot patent anandamide, the endocannabinoid your body produces naturally, or 2-AG, another key endocannabinoid, or the receptors they bind to. Pharmaceutical research is driven by the possibility of creating proprietary compounds that can be protected and monetised. A biological system that the body already possesses, one that can be supported by plant compounds that have existed for thousands of years, does not fit that model. There is no financial incentive to spend billions educating the medical community about something that cannot be owned.
That is not a conspiracy theory. It is a structural reality of how pharmaceutical research is funded and directed.
The receptor network that reaches everywhere
One of the most striking facts about the ECS is simply how many receptors it operates through, and how widely distributed those receptors are throughout the body.
Central Nervous System
Found in extraordinary density in the brain. Present in the hippocampus, cortex, cerebellum, basal ganglia, and brainstem. Also present in the liver, fat cells, muscles, and gastrointestinal tract.
Immune & Peripheral Tissues
Concentrated in immune cells and peripheral tissues, particularly those involved in inflammation. Found in the spleen, tonsils, thymus, and throughout the gut-associated lymphoid tissue.
Pain & Temperature
Regulates pain transmission and the body's response to temperature changes.
The Third Receptor
Sometimes called the third cannabinoid receptor, influences bone health and blood pressure.
Metabolism
Affects metabolism, fat storage, and inflammatory pathways at the cellular level.
Serotonin Receptors
Regulate mood, anxiety, and stress responses through interaction with the ECS.
The reason this matters is that it explains why phytocannabinoid support can have such wide-ranging effects across apparently unrelated systems. It is not because cannabinoids are doing many different things. It is because they are supporting one system that was already doing all of those things.
When the system runs low
Researchers including Dr. Ethan Russo have developed the theory of Clinical Endocannabinoid Deficiency, the idea that a chronically underactive ECS may be a root cause or contributing factor in a range of conditions that have historically been difficult to treat with conventional approaches.
Conditions associated with potential endocannabinoid deficiency include fibromyalgia, migraine, irritable bowel syndrome, and certain mood disorders. What these conditions share in common is that they are often described as conditions of hypersensitivity or dysregulation, where the body's ability to calibrate its own responses to pain, stress, and immune activity has broken down.
The conventional medical approach to each of these conditions is to treat the downstream symptom, to suppress the pain, dampen the immune response, or manage the mood. The ECS framework asks a different question: what if the regulatory system responsible for calibrating all of those responses is simply not functioning at full capacity? And what if supporting that system, rather than overriding its outputs, is a more effective long-term approach?
Hemp and cannabis: an important distinction
Before we go further, there is something that needs to be said clearly, because confusion on this point has caused many people to dismiss something that could genuinely help them.
Hemp and cannabis are not the same thing.
Both come from the same plant species, Cannabis sativa L., but they are fundamentally different varieties with fundamentally different profiles. What most people think of when they hear the word "cannabis" is a THC-dominant plant, the variety associated with intoxication, recreational use, and the legal controversy that has surrounded it for most of the past century. THC (tetrahydrocannabinol) is the compound that produces psychoactive effects. It is what gets people stoned.
Hemp is a different variety of the same species. It is naturally very low in THC and rich in non-psychoactive phytocannabinoids including CBD, CBG, CBN, CBDa, and others. Hemp does not impair cognitive function. It does not alter perception. It does not produce intoxication of any kind. It has been grown for thousands of years for fibre, food, and medicine.
The legal framework in the United States now reflects this distinction. The 2018 Agricultural Improvement Act, commonly known as the Farm Bill, federally legalised hemp and hemp-derived products containing less than 0.3% THC. Our formulations are derived from legally cultivated hemp and contain no detectable THC. They are fully compliant with federal law.
The reason this distinction matters so much is that decades of stigma around cannabis, driven by its association with intoxication and its Schedule I classification, have caused many people to reflexively dismiss anything connected to the plant family, including compounds that have nothing to do with getting high and everything to do with supporting the biology your body already relies on.
Phytocannabinoids: supporting what your body already makes
Phytocannabinoids are plant-derived compounds that interact with the endocannabinoid system. The reason they can do this is not because they are foreign chemicals forcing a biological response. It is because their molecular structure is remarkably similar to the endocannabinoids your body produces naturally.
Think of it this way. Your body makes its own signalling molecules, anandamide and 2-AG, to activate the ECS. When levels of these endocannabinoids are low, the system underperforms. Phytocannabinoids from hemp closely mimic these natural molecules in structure, allowing them to interact with the same receptors and support the same signalling pathways. They are not introducing a foreign process. They are supplementing one that already exists, in much the same way that taking magnesium supplements supports a process your body was already trying to run with insufficient raw materials.
This is why our formulations are not drugs. They do not override or block a biological pathway the way most pharmaceuticals do. They support and activate a system your body already owns, using compounds that nature has structured to be compatible with it.
The most widely known phytocannabinoid is CBD (cannabidiol). But the science increasingly shows that CBD alone, in isolate form, captures only a fraction of what is possible. The full spectrum of phytocannabinoids, working together, produces effects that exceed any single compound in isolation. This is called the entourage effect, and it mirrors the way the ECS itself operates, through a network of coordinated signals rather than a single switch.
Cannabigerol
Studied for its neuroprotective properties and its influence on CB2-mediated inflammatory responses.
Cannabinol
Associated with sleep regulation and immune support across multiple pathways.
Cannabidiolic Acid
The acidic precursor to CBD, modulates COX-2 enzymes, the same pathway targeted by common anti-inflammatory drugs, but without the gastrointestinal damage.
Cannabicyclol
Completes the full-spectrum profile of our formulations as part of the entourage effect.
Most CBD products on the market are isolates or broad-spectrum products that strip out many of these compounds during processing. Our formulations are designed to preserve the full phytocannabinoid profile, because the evidence points clearly to the full profile as the more effective approach.
What makes Reset ECS formulations different
The market for CBD and hemp products has grown enormously over the past decade. It has also become crowded with products that are, in plain terms, unlikely to do very much. Understanding the difference matters if you are serious about supporting your ECS.
Most commercially available CBD products are isolates, meaning they contain only CBD, stripped of the other phytocannabinoids that contribute to the entourage effect. They are often derived from low-quality hemp, processed in ways that reduce the active compound profile, and dosed at levels too low to produce any meaningful physiological response. They are frequently marketed with claims that outrun the science, and just as frequently, they disappoint the people who try them.
Our formulations are different in several specific ways.
First, the full phytocannabinoid profile
They contain CBD, CBG, CBN, CBDa, and CBL working in combination. This is not accidental. It is the result of deliberate formulation designed around the entourage effect.
Second, transdermal delivery
They are delivered through the skin, in formats specifically designed to reach the receptor layer efficiently. The Kaneh Bosem Oil is a fast-absorbing transdermal formulation. The Beeswax Salve is a denser protective formulation for sustained delivery. Both are designed to localise effect at the tissue level while also supporting systemic ECS signalling.
Third, clinical formulation expertise
They are formulated by someone with 25 years of clinical experience in pharmaceutical science, autoimmune disease, and oncology, who developed the protocol first on himself, following a stroke, before offering it to others. This is not a product created in a laboratory by people who have never used it. It is a protocol built from necessity, refined through experience, and grounded in science.
From the formulator
The person who formulated our protocols is Barry Bonner. Barry spent 25 years working in clinical medicine, in autoimmune disease, oncology, and pharmaceutical science, before suffering a stroke in 2017. In the years that followed, he undertook his own research into the ECS, the gut-brain axis, and the role of phytocannabinoids in neurological recovery.
What he discovered informed not just his own recovery, but the entire framework that became the Reset ECS protocol. This is not a business built from the outside in. It is built from lived experience, clinical knowledge, and a genuine conviction that the endocannabinoid system represents one of the most important and most underutilised tools available to anyone seeking to support their health from the inside out.
The ECS was always there. It was always working for you. We are here to help it work better.